Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $131.37 million. The enterprise value is $117.01 million.
| Market Cap | 131.37M |
| Enterprise Value | 117.01M |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, after market close.
| Earnings Date | May 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 173.86 million shares outstanding. The number of shares has increased by 13.42% in one year.
| Shares Outstanding | 173.86M |
| Shares Change (YoY) | +13.42% |
| Shares Change (QoQ) | -6.69% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 18.15% |
| Float | 156.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 45.87 |
| PS Ratio | 18.52 |
| Forward PS | 9.09 |
| PB Ratio | 2.36 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.32, with a Debt / Equity ratio of 0.35.
| Current Ratio | 3.32 |
| Quick Ratio | 3.11 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -108.50% and return on invested capital (ROIC) is -107.00%.
| Return on Equity (ROE) | -108.50% |
| Return on Assets (ROA) | -73.30% |
| Return on Capital (ROIC) | -107.00% |
| Revenue Per Employee | $67,697 |
| Profits Per Employee | -$756,560 |
| Employee Count | 109 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $261,000 in taxes.
| Income Tax | 261,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.79% in the last 52 weeks. The beta is 0.56, so Vaxart's price volatility has been lower than the market average.
| Beta (1Y) | 0.56 |
| 52-Week Price Change | +21.79% |
| 50-Day Moving Average | 1.17 |
| 200-Day Moving Average | 0.85 |
| Relative Strength Index (RSI) | 25.95 |
| Average Volume (30 Days) | 1,929,558 |
Short Selling Information
The latest short interest is 17.19 million, so 9.89% of the outstanding shares have been sold short.
| Short Interest | 17.19M |
| Short Previous Month | 15.61M |
| Short % of Shares Out | 9.89% |
| Short % of Float | 10.95% |
| Short Ratio (days to cover) | 10.91 |
Income Statement
In the last 12 months, Vaxart had revenue of $7.38 million and -$82.47 million in losses. Loss per share was -$0.57.
| Revenue | 7.38M |
| Gross Profit | 7.38M |
| Operating Income | -83.35M |
| Pretax Income | -82.20M |
| Net Income | -82.47M |
| EBITDA | -73.58M |
| EBIT | -82.20M |
| Loss Per Share | -$0.57 |
Balance Sheet
The company has $39.71 million in cash and $20.09 million in debt, giving a net cash position of $19.63 million or $0.11 per share.
| Cash & Cash Equivalents | 39.71M |
| Total Debt | 20.09M |
| Net Cash | 19.63M |
| Net Cash Per Share | $0.11 |
| Equity / Book Value | 57.81M |
| Book Value Per Share | 0.33 |
| Working Capital | 31.81M |
Cash Flow
In the last 12 months, operating cash flow was -$70.45 million and capital expenditures -$1.75 million, giving a free cash flow of -$72.20 million.
| Operating Cash Flow | -70.45M |
| Capital Expenditures | -1.75M |
| Free Cash Flow | -72.20M |
| FCF Per Share | -$0.50 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,129.52% and -1,117.56%.
| Gross Margin | 100.00% |
| Operating Margin | -1,129.52% |
| Pretax Margin | -1,114.03% |
| Profit Margin | -1,117.56% |
| EBITDA Margin | -997.15% |
| EBIT Margin | -1,114.03% |
| FCF Margin | -978.51% |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.42% |
| Shareholder Yield | -13.42% |
| Earnings Yield | -60.35% |
| FCF Yield | -52.84% |
Analyst Forecast
The average price target for Vaxart is $3.00, which is 292.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 292.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 60.39% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 14, 2018. It was a reverse split with a ratio of 1:11.
| Last Split Date | Feb 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:11 |
Scores
Vaxart has an Altman Z-Score of -6.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.29 |
| Piotroski F-Score | 3 |